يعرض 1 - 20 نتائج من 86 نتيجة بحث عن '"Dwamena, Ben A."', وقت الاستعلام: 0.60s تنقيح النتائج
  1. 1
    Academic Journal

    وصف الملف: application/pdf

    Relation: Greenhawt, Matthew; Shaker, Marcus; Golden, David B. K.; Abrams, Elissa M.; Blumenthal, Kimberly G.; Wolfson, Anna R.; Stone, Cosby A.; Krantz, Matthew S.; Chu, Derek K.; Dwamena, Ben A. (2023). "Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: A systematic review and meta-analysis." Allergy (1): 71-83.; https://hdl.handle.net/2027.42/175406; Allergy; McSweeney MD, Mohan M, Commins SP, Lai SK. Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy. Brief Research Report. Front Allergy. 2021; 2: 715844. doi:10.3389/falgy.2021.715844; Park HJ, Montgomery JR, Boggs NA. Anaphylaxis after the Covid-19 vaccine in a patient with cholinergic urticaria. Mil Med. 2021. doi:10.1093/milmed/usab138; Loli-Ausejo D, Gonzalez de Abreu JM, Fiandor A, et al. Allergic reactions after administration of pfizer-biontech covid-19 vaccine to healthcare workers at a tertiary hospital. J Investig Allergol Clin Immunol. 2021; 31: 507 - 508. doi:10.18176/jiaci.0751; Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report. Ann Allergy Asthma Immunol. 2021; 126 ( 6 ): 735 - 738. doi:10.1016/j.anai.2021.03.012; Kohli-Pamnani A, Zapata K, Gibson T, Kwittken PL. Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing. Ann Allergy Asthma Immunol. 2021; 128: 97 - 98. doi:10.1016/j.anai.2021.08.417; Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021; 4 ( 9 ): e2125524. doi:10.1001/jamanetworkopen.2021.25524; Carpenter T, Konig J, Hochfelder J, Siegel S, Gans M. Polyethylene glycol and polysorbate testing in twelve patients prior to or after COVID-19 vaccine administration. Ann Allergy Asthma Immunol. 2021; 128: 99 - 101. doi:10.1016/j.anai.2021.10.009; Kaplan B, Farzan S, Coscia G, et al. Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience. Ann Allergy Asthma Immunol. 2022; 128 ( 2 ): 161 - 168.e1. doi:10.1016/j.anai.2021.10.019; ALMuhizi F, Fein M, Gabrielli S, et al. Allergic reactions to the COVID-19 vaccine (ARCOV) study: the McGill University Health Center (MUHC) experience. Ann Allergy Asthma Immunol. 2022; 129: 182 - 188.e1.; Van Meerbeke SW, Fajt ML, Marini RV, Domsic RT, Petrov AA. Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose. Ann Allergy Asthma Immunol. 2022; 129: 373 - 374. doi:10.1016/j.anai.2022.05.004; Otani IM, Tsao LR, Tang M. Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics. Ann Allergy Asthma Immunol. 2022; 129 ( 1 ): 88 - 94.e1.; Csuth À, Nopp A, Storsaeter J, Nilsson L, Jenmalm MC. COVID-19 vaccines and anaphylaxis-evaluation with skin prick testing, basophil activation test and immunoglobulin E. Clin Exp Allergy. 2022; 52 ( 6 ): 812 - 819.; Cahill JA, Kan M. Successful administration of second dose of BNT162b2 COVID-19 vaccine in two patients with potential anaphylaxis to first dose. Allergy. 2022; 77 ( 1 ): 337 - 338.; Murphy KR, Patel NC, Ein D, et al. Insights from American College of Allergy, asthma, and immunology COVID-19 vaccine task force: allergic reactions to mRNA SARS-CoV-2 vaccines. Ann Allergy Asthma Immunol. 2021; 126 ( 4 ): 319 - 320. doi:10.1016/j.anai.2021.01.017; https://educationaaaaiorg/resources-for-a-i-clinicians/reactionguidance_COVID-19. Accessed September 2, 2021.; https://www.csaci.ca/wp-content/uploads/2021/11/2021-11-15-UPDATE-COVID-19-Vaccine-Testing-Administration-Guidance.pdf. Accessed December 10, 2021.; Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021; 51 ( 6 ): 861 - 863. doi:10.1111/cea.13874; Rush C, Faulk KE, Bradley ZK, Turner A, Krumins M, Greenhawt M. The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: a single institution experience. J Allergy Clin Immunol Pract. 2022; 10 ( 2 ): 630 - 632. doi:10.1016/j.jaip.2021.11.025; Mark C, Gupta S, Punnett A, et al. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer. 2021; 68 ( 11 ): e29295. doi:10.1002/pbc.29295; Koo G, Anvari S, Friedman DL, et al. mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. J Allergy Clin Immunol Pract. 2022; 10 ( 1 ): 322 - 325. doi:10.1016/j.jaip.2021.09.051; Brockow K, Mathes S, Fischer J, et al. Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis. Allergy. 2021; 77: 2200 - 2210. doi:10.1111/all.15183; Picard M, Drolet JP, Masse MS, et al. Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series. J Allergy Clin Immunol Pract. 2022; 10 ( 2 ): 620 - 625.e1. doi:10.1016/j.jaip.2021.11.021; Bruusgaard-Mouritsen MA, Koo G, Heinrichsen AS, et al. Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy. J Allergy Clin Immunol Pract. 2022; 10 ( 3 ): 859 - 862. doi:10.1016/j.jaip.2021.12.025; Sellaturay P, Gurugama P, Harper V, Dymond T, Ewan P, Nasser S. The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Clin Exp Allergy. 2022; 52 ( 1 ): 12 - 17. doi:10.1111/cea.14064; Vidal Oribe I, Venturini Diaz M, Hernandez Alfonso P, Del Pozo Gil MD, Gonzalez Mahave I, Lobera LT. Tolerance of SARS CoV-2 vaccines with polyethylene glycol in allergic patients to polysorbate 80. J Investig Allergol Clin Immunol. 2021; 32 ( 5 ): 403 - 405. doi:10.18176/jiaci.0772; https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed January 26, 2021.; Banerji A, Wolfson AR, Robinson LB, et al. COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy. Allergy. 2022; 77 ( 3 ): 1048 - 1051.; Nelson HS, Lahr J, Buchmeier A, McCormick D. Evaluation of devices for skin prick testing. J Allergy Clin Immunol. 1998; 101 ( 2 Pt 1 ): 153 - 156. doi:10.1016/S0091-6749(98)70409-9; Carr WW, Martin B, Howard RS, et al. Comparison of test devices for skin prick testing. J Allergy Clin Immunol. 2005; 116 ( 2 ): 341 - 346. doi:10.1016/j.jaci.2005.03.035; Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute allergic reactions: a multidisciplinary Delphi study. J Allergy Clin Immunol. 2021; 148 ( 1 ): 173 - 181. doi:10.1016/j.jaci.2021.01.003; Marcelino J, Farinha S, Silva R, Didenko I, Proença M, Tomás E. Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine. J Allergy Clin Immunol Pract. 2021; 9 ( 6 ): 2476 - 2477. doi:10.1016/j.jaip.2021.03.022; Johns Hopkins University Coronavirus Resource Center. Accessed September 28, 2021. https://coronavirusjhuedu/maphtml; Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021; 9: 3546 - 3567. doi:10.1016/j.jaip.2021.06.006; Chu DK, Abrams EM, Golden DBK, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis. JAMA Intern Med. 2022; 182 ( 4 ): 376 - 385. doi:10.1001/jamainternmed.2021.8515; CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 125 - 129. doi:10.15585/mmwr.mm7004e1; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html. Accessed September 20, 2021.; https://www.gov.uk/government/news/confirmation-of-guidance-to-vaccination-centres-on-managing-allergic-reactions-following-covid-19-vaccination-with-the-pfizer-biontech-vaccine. Accessed December 15, 2020.; Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021; 9 ( 4 ): 1423 - 1437. doi:10.1016/j.jaip.2020.12.047; Banerji A, Wolfson AR, Wickner PG, et al. COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach. J Allergy Clin Immunol Pract. 2021; 9 ( 6 ): 2135 - 2138. doi:10.1016/j.jaip.2021.03.053; Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012; 130 ( 1 ): 25 - 43. doi:10.1016/j.jaci.2012.04.003; Dwamena BA. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. Statistical Software Components S456880, Boston College Department of Economics, revised 05 Feb 2009. Accessed August 24, 2018. 2007.; Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006; 59 ( 12 ): 1331 - 1332; author reply 1332–1333. doi:10.1016/j.jclinepi.2006.06.011; Arends LR, Hamza TH, van Houwelingen JC, Heijenbrok-Kal MH, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of ROC curves. Med Decis Making. 2008; 28 ( 5 ): 621 - 638. doi:10.1177/0272989X08319957; Grant R, Carpenter B, Furr DC, Gelman A. Introducing the StataStan interface for fast, complex bayesian modeling using Stan. Stata J. 2017; 17 ( 2 ): 330 - 342.; Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Chapman & Hall/CRC; 2014.; Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Statist Sci. 1992; 7 ( 4 ): 457 - 472. doi:10.1214/ss/1177011136; Chu DK, Golden DBK, Guyatt GH. Translating evidence to optimize patient care using GRADE. J Allergy Clin Immunol Pract. 2021; 9 ( 12 ): 4221 - 4230. doi:10.1016/j.jaip.2021.09.035; Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155 ( 8 ): 529 - 536. doi:10.7326/0003-4819-155-8-201110180-00009; Tuong LAC, Capucilli P, Staicu M, Ramsey A, Walsth E, Mustafa SS. Graded administration of second dose of Moderna and Pfizer-BioNTech COVID-19 mRNA vaccine in patients with hypersensitivity to first dose. Open Forum Infect Dis. 2021; 8: ofab507.; Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose! Allergy. 2021; 76 ( 9 ): 2916 - 2920. doi:10.1111/all.14958; Rasmussen TH, Mortz CG, Georgsen TK, Rasmussen HM, Kjaer HF, Bindslev-Jensen C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021; 11 ( 5 ): e12044. doi:10.1002/clt2.12044; Wolfson AR, Robinson LB, Li L, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021; 9 ( 9 ): 3308 - 3320.e3. doi:10.1016/j.jaip.2021.06.010; Kessel A, Bamberger E, Nachshon L, Rosman Y, Confino-Cohen R, Elizur A. Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose. Allergy. 2021; 76: 3538 - 3540. doi:10.1111/all.15038; Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021; 127 ( 1 ): 133 - 134. doi:10.1016/j.anai.2021.03.024; Mustafa SS, Ramsey A, Staicu ML. Administration of a second dose of the Moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports. Ann Intern Med. 2021; 174 ( 8 ): 1177 - 1178. doi:10.7326/L21-0104; Vanijcharoenkarn K, Lee FE, Martin L, Shih J, Sexton ME, Kuruvilla ME. Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration. Clin Infect Dis. 2021; 73: 2108 - 2111. doi:10.1093/cid/ciab448

  2. 2
    Academic Journal
  3. 3
    Academic Journal

    المساهمون: Foerster, Bradley R., Dwamena, Ben A., Petrou, Myria, Carlos, Ruth C., Callaghan, Brian C., Churchill, Christina L., Mohamed, Mona A., Bartels, Claudia, Benatar, Michael, Bonzano, Laura, Ciccarelli, Olga, Cosottini, Mirco, Ellis, Cathy M., Ehrenreich, Hannelore, Filippini, Nicola, Ito, Mizuki, Kalra, Sanjay, Melhem, Elias R., Pyra, Timothy, Roccatagliata, Luca, Senda, Joe, Sobue, Gen, Turner, Martin R., Feldman, Eva L., Pomper, Martin G.

  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal

    المساهمون: Veterans Health Administration, National Institutes of Health, University of Colorado Department of Medicine Outstanding Early Career Scholar Program

    المصدر: Clinical Gastroenterology and Hepatology ; volume 16, issue 9, page 1529-1530 ; ISSN 1542-3565

  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal

    مصطلحات موضوعية: DLB, MCI, PDD, Parkinson's disease, systematic review, Health Sciences

    وصف الملف: application/pdf

    Relation: Petrou, Myria; Dwamena, Ben A.; Foerster, Bradley R.; MacEachern, Mark P.; Bohnen, Nicolaas I.; Müller, Martijn Ltm; Albin, Roger L.; Frey, Kirk A. (2015). "Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review." Movement Disorders 30(7): 928-935.; https://hdl.handle.net/2027.42/111915; Movement Disorders; Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52: 1210 ‐ 1217.; Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965 ‐ 973.; Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85 ‐ 91.; Rowe CC, Ng S, Ackermann U, et al. Imaging beta‐amyloid burden in aging and dementia. Neurology 2007; 68: 1718 ‐ 1725.; Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331 ‐ 1338.; Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB‐, [(18)F]FDG‐PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010; 16: 666 ‐ 670.; Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Abeta‐amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79: 1161 ‐ 1167.; Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.; Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140 ‐ 148.; Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242 ‐ 251.; American Psychiatric Association. Diagnostic criteria from DSM‐IV‐TR. 2000, Washington, DC: American Psychiatric Association, xii, 370 p.; Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557 ‐ 560.; Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097 ‐ 1105.; Jack CR, Jr., Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging‐Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765 ‐ 775.; Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18‐labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398 ‐ 1403.; Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta‐amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 68: 232 ‐ 240.; Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446 ‐ 452.; Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population‐based study of cognitively normal elderly. Neurology 2012; 79: 1570 ‐ 1577.; Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122 ‐ 131.; Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275 ‐ 1283.; Fleisher AS, et al. Florbetapir PET analysis of amyloid‐beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross‐sectional study. Lancet Neurol 2012; 11: 1057 ‐ 1065.; Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age‐specific population frequencies of cerebral beta‐amyloidosis and neurodegeneration among people with normal cognitive function aged 50‐89 years: a cross‐sectional study. Lancet Neurol 2014; 13: 997 ‐ 1005.; Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837 ‐ 844.; Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid‐beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 2011; 108: 14968 ‐ 14973.; Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Albin RL. Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. Arch Neurol 2012; 69: 1628 ‐ 1631.; Scheinin NM, Wikman K, Jula A, et al. Cortical 11 C‐PIB uptake is associated with age, APOE genotype, and gender in “healthy aging.” J Alzheimers Dis 2014; 41: 193 ‐ 202.; Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409 ‐ 415.; Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh‐Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8‐year prospective study. Arch Neurol 2003; 60: 387 ‐ 392.; Boot B. The incidence and prevalence of dementia with Lewy bodies is underestimated. Psychol Med 2013; 43: 2687 ‐ 2688.; Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44: 673 ‐ 683.; McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863 ‐ 1872.; Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 2009; 24: 114 ‐ 125.; Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812 ‐ 819.; Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122: 187 ‐ 204.; Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007; 13 (Suppl 3 ): S221 ‐ S224.; Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B. Ann Neurol 2004; 55: 306 ‐ 319.; Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy‐ and Alzheimer‐type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493 ‐ 1505.; Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta‐amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008; 67: 155 ‐ 161.; Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011; 134 (Pt 6 ): 1647 ‐ 1657.; Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33: 2091 ‐ 2105.; Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer‐like characteristics. Neurobiol Dis 2009; 34: 107 ‐ 112.; Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body‐associated disorders. Mov Disord 2010; 25: 2516 ‐ 2523.; Shimada H, Shinotoh H, Hirano S, et al. beta‐Amyloid in Lewy body disease is related to Alzheimer's disease‐like atrophy. Mov Disord 2013; 28: 169 ‐ 175.

  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Book
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20
    Academic Journal